Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients

This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2006-08, Vol.28 (8), p.1175-1180
Main Authors: Grossman, Ronald F., Ambrusz, Mary E., Fisher, Alan C., Khashab, Mohammed M., Kahn, James B.
Format: Article
Language:English
Subjects:
acute bacterial exacerbation of chronic bronchitis
Aged
Amoxicillin-Potassium Clavulanate Combination - administration & dosage
amoxicillin/clavulanate
Anti-Bacterial Agents - administration & dosage
Bacterial Infections - drug therapy
Biological and medical sciences
Bronchitis - drug therapy
Chronic Disease
Chronic obstructive pulmonary disease, asthma
Drug Administration Schedule
Female
Humans
Levofloxacin
Male
Medical sciences
Ofloxacin - administration & dosage
Pharmacology. Drug treatments
Pneumology
short-course
tolerability
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This post hoc analysis of data from a previous randomized, blinded, multicenter, parallel, noninferiority study assessed the bacterial etiology, symptom resolution, and tolerability of severe acute bacterial exacerbation of chronic bronchitis (ABECB) patients treated with either levofloxacin 750 mg QD for 5 days or amoxicillin/clavulanate 875 mg/125 mg BID for 10 days. Severe ABECB was defined as ABECB and forced expiratory volume in 1 second (FEV1)
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2006.08.013